Hematology-Oncologyibrutinib resistanceBệnh bạch cầu lympho mạn tính dòng B (Chronic Lymphocytic Leukemia
Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance
By MedXY|Sep 28, 2026
Aberrant MERTK expression activates BCR signaling via CD79a in CLL, offering a novel therapeutic target. Inhibiting MERTK with UNC-2025 shows potential against ibrutinib-resistant relapse, especially combined with venetoclax.